# Inside the KLOW Peptide Stack: The Four Peptides — Composition and Mechanisms > The KLOW stack contains KPV, GHK-Cu, BPC-157 and TB-500 at 50/10/10/10 mg in an 80 mg vial. This page maps each peptide's mechanism, published evidence, and the pharmacokinetic mismatch that is inherent in co-formulating them. Four distinct compounds pressed into one vial — each with its own mechanism, its own literature, and its own honest evidence profile. ## In plain English The KLOW stack is four peptides in one vial. KPV is the anti-inflammatory arm — a three-amino-acid fragment that dials down inflammation in gut and immune cells. GHK-Cu is the skin and matrix arm — the copper-chelated tripeptide that reshapes collagen and gene expression, and makes up most of the vial by weight. BPC-157 is the angiogenic and tendon-repair arm — it tells cells to grow new blood vessels and repairs tendons in rat studies. TB-500 is the wound-closure arm — a fragment of a protein that helps cells migrate to close wounds. They were designed to cover four separate steps of repair. Whether they actually work better together than any one alone is a question no study has answered. ## KPV — the anti-inflammatory arm **KPV** (Lys-Pro-Val) is the C-terminal tripeptide (residues 11-13) of alpha-MSH (alpha-melanocyte-stimulating hormone, a 13-residue regulatory peptide). Molecular weight: 342.44 Da. CAS: 67727-97-3. Role in the blend: anti-inflammatory. Its studied mechanism is inhibition of NF-kappaB nuclear import — blocking the transcription factor (NF-kappaB) that switches on inflammatory genes — and suppression of MAPK inflammatory signaling, with downstream reductions in TNF-alpha, IL-6, IL-1beta and IL-8 [3]. Uptake: KPV is a substrate of PepT1 (SLC15A1), the intestinal di/tripeptide transporter that is upregulated in inflamed gut epithelium, with a Km of approximately 160 micromolar. This transporter-mediated uptake is the mechanistic basis for its gut-targeted anti-inflammatory effect [3]. Evidence level: human intestinal cell cultures and mouse colitis models. No approved human indication. 10 mg in the canonical 80 mg KLOW vial. ## GHK-Cu — the skin-matrix arm **GHK-Cu** (Gly-His-Lys copper(II) complex, Copper Tripeptide-1) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. Molecular weight: 402.92 Da. CAS: 89030-95-5. Role in the blend: skin-matrix and gene-expression modulator, and the mass-dominant component (50 of 80 mg, 62.5% by mass). At low-nanomolar concentrations in fibroblasts, GHK modulates approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold [5]. The strongest signals are on extracellular-matrix remodeling, antioxidant defense, DNA repair and anti-inflammatory programs. It stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin [4], and supplies copper for lysyl oxidase — the copper-dependent enzyme that crosslinks collagen and elastin. Plasma GHK declines from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 [4], a decline associated with age-related shifts in fibroblast behavior. Topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid in a placebo-controlled comparison [4]. Evidence level: extensive topical human cosmetic data; in vitro gene-expression studies; one penetration study quantifying topical copper delivery [8]; 2024–2025 mechanistic and formulation reviews [11, 12]. No systemic human indication approved. ## BPC-157 — the angiogenic repair arm **BPC-157** (Body Protection Compound 157, pentadecapeptide, PL 14736) is a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of a protein identified in human gastric juice. Molecular weight: 1419.53 Da. CAS: 137525-51-0. Role in the blend: angiogenic and tissue-repair arm. Primary mechanism: VEGFR2/PI3K/Akt/eNOS activation — driving new blood-vessel formation from existing vessels. Also upregulates the growth-hormone receptor in tendon fibroblasts and modulates the nitric-oxide system in a manner partly resistant to L-NAME [2]. Key result: accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and histological measures at doses from 10 μg down to 10 pg per rat once daily IP [2]. Evidence level: extensive rodent model data; one 2025 two-person IV safety pilot [6]; one 2024 uncontrolled interstitial cystitis pilot [13]. FDA 503A category 2. 10 mg in the canonical KLOW vial. ## TB-500 — the cytoskeletal wound-closure arm **TB-500** (Ac-LKKTETQ) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of thymosin beta-4 (Tbeta4, the full-length 43-amino-acid native protein). Molecular weight: 889.02 Da. No CAS number issued for the fragment. Role in the blend: cytoskeletal and wound-closure arm. The LKKTET motif sequesters G-actin (monomeric actin), holding it in reserve for cell migration and re-epithelialization. Full-length thymosin beta-4 additionally activates integrin-linked kinase (ILK) and mobilizes epicardial progenitors — activities not demonstrated for the TB-500 fragment [1]. Key result: topical or IP thymosin beta-4 (full-length) increased re-epithelialization by 42% at 4 days and 61% at 7 days in a rat wound model, increased contraction (≥11% at day 7) and stimulated keratinocyte migration at as little as 10 pg [1]. These findings apply to the native full-length protein. Critical compliance note: thymosin beta-4 / TB-500 is listed on the WADA Prohibited List (S2, peptide hormones and growth factors), banned at all times in and out of competition [7]. 10 mg in the canonical KLOW vial. Evidence level: extensive rodent and ex vivo data for full-length Tbeta4; limited fragment-specific data. ## KLOW vs GLOW KLOW and GLOW are related but distinct research blends. GLOW contains GHK-Cu, BPC-157, and TB-500 — three of the four KLOW components — but does not include KPV. The addition of KPV is the structural difference that defines KLOW versus GLOW. In research-use community accounts, the KPV arm is often credited with giving KLOW a more pronounced anti-inflammatory character than GLOW — a perceived difference in the 'feel' of the two stacks, attributed to KPV's NF-kappaB-suppressive effect. This is anecdotal community comparison, not a head-to-head controlled study. KLOW is not WOLVERINE, which is a separate research blend with a different composition. These three blends are distinct research formulations, each with its own component profile and its own absent combination trial. ## The pharmacokinetic mismatch A co-formulated vial cannot overcome the pharmacokinetic reality: the four KLOW peptides clear at very different rates. The tripeptides KPV and GHK-Cu are small (342 and 402 Da respectively) and clear quickly. BPC-157's formal rat-plasma half-life from the published PK study is under approximately 30 minutes. The TB-500 fragment behaves differently from full-length thymosin beta-4 (43 amino acids), and its pharmacokinetics have not been formally characterized. The consequence: a single co-formulated dose will not maintain all four components at meaningful concentrations in any target tissue simultaneously. Whether sequential rather than simultaneous exposure achieves the desired four-arm effect — and whether the pharmacokinetics are even relevant to the claimed mechanisms — is not known. No study has addressed this question for KLOW. --- A letterpress reading-record that presses each of the four KLOW components against its own cited studies, leaves the absent blend trial as the single most prominent blank on the page, and operates no clinic, counter, or dispensary behind the impressed type.